- Home
- RDHL vs TCRT Comparison
RDHL vs TCRT Comparison
Compare RDHL & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- TCRT
- Stock Information
- Founded
- RDHL 2009
- TCRT 1998
- Country
- RDHL Israel
- TCRT United States
- Employees
- RDHL N/A
- TCRT N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- TCRT Health Care
- Exchange
- RDHL Nasdaq
- TCRT Nasdaq
- Market Cap
- RDHL 3.8M
- TCRT 3.8M
- IPO Year
- RDHL N/A
- TCRT N/A
- Fundamental
- Price
- RDHL $1.85
- TCRT $5.02
- Analyst Decision
- RDHL
- TCRT
- Analyst Count
- RDHL 0
- TCRT 0
- Target Price
- RDHL N/A
- TCRT N/A
- AVG Volume (30 Days)
- RDHL 18.5K
- TCRT 45.5K
- Earning Date
- RDHL 04-10-2025
- TCRT 08-13-2025
- Dividend Yield
- RDHL N/A
- TCRT N/A
- EPS Growth
- RDHL N/A
- TCRT N/A
- EPS
- RDHL N/A
- TCRT N/A
- Revenue
- RDHL $8,042,999.00
- TCRT $11,000.00
- Revenue This Year
- RDHL $381.91
- TCRT $5,680,500.00
- Revenue Next Year
- RDHL N/A
- TCRT N/A
- P/E Ratio
- RDHL N/A
- TCRT N/A
- Revenue Growth
- RDHL 23.17
- TCRT 83.33
- 52 Week Low
- RDHL $1.71
- TCRT $1.31
- 52 Week High
- RDHL $20.28
- TCRT $7.40
- Technical
- Relative Strength Index (RSI)
- RDHL 43.03
- TCRT 76.09
- Support Level
- RDHL $1.72
- TCRT $3.00
- Resistance Level
- RDHL $2.08
- TCRT $4.92
- Average True Range (ATR)
- RDHL 0.09
- TCRT 0.63
- MACD
- RDHL 0.01
- TCRT 0.18
- Stochastic Oscillator
- RDHL 27.78
- TCRT 98.55
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.